- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04455737
Ex Vivo Intra-arterial Indigo Carmine Injection After Transanal Total Mesorectal Excision (RLF)
Background: An exact lymph node staging is essential in the treatment of rectal cancer.
Objective: The aim of this study was to assess the effect of indigo carmine injection on the number of retrieved and positive lymph nodes after transanal total mesorectal excision (taTME).
Design: This is a retrospective, non-randomised study. Settings: This study was conducted at a tertiary hospital by a multidisciplinary team.
Patients: Between 2013 and 2019, patients undergoing transanal total mesorectal excision were analysed. Patients with indigo carmine injection (intervention group) were compared to those without (control group).
Interventions: Transanal total mesorectal excision was performed with or without ex vivo intra-arterial indigo carmine injection.
Main Outcome Measures: The number of retrieved and positive lymph nodes was the primary outcome measure.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Rorschach, Switzerland, 9400
- Department of General, Visceral, Endocrine and Transplantation Surgery, Cantonal Hospital St. Gallen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- elective, oncologic rectum resection in TaTME technique for proven or highly suspected rectal cancer.
Exclusion Criteria:
- abdominoperineal resection
- extended colon resection
- previous surgery of the rectum, the left colon or the mesocolon/-rectum
- patients rejecting retrospective data analysis
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with indigo carmine stained specimen
Specimen which underwent pathologic work-up after ex vivo indigo carmine injection into the inferior mesenteric artery after transanal total mesorectal excision.
|
Ex vivo intra-arterial injection of 20 ml indigo carmine solution (10mL, 0.4% indigo carmine with 10mL, 0.9% saline solution) in the transanal total mesorectal excision specimen via the inferior mesenteric artery.
|
Patients with unstained specimen
Specimen which underwent pathologic work-up after transanal total mesorectal excision without indigo carmine dyeing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
retrieved lymph nodes
Time Frame: 1 - 7 days after surgery
|
number of lymph nodes retrieved by pathologist from the specimen
|
1 - 7 days after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
survival
Time Frame: 5 years
|
overall survival
|
5 years
|
positive lymph nodes
Time Frame: 1 - 7 days after surgery
|
number of lymph nodes with microscopic tumor infiltration
|
1 - 7 days after surgery
|
N stage
Time Frame: 1 - 7 days after surgery
|
N stage according TNM version 7
|
1 - 7 days after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Walter Brunner, MD MSc MBA, Kantonsspital St. Gallen, Rorschach branch, Department of Surgery
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Chir202001
- 2020-01324 (Other Identifier: Swissethics BASEC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Neoplasms
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
SafeHeal IncTerminatedSafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study (SAFE-2)Colorectal Cancer | Rectal Cancer | Rectal Tumor | Rectal/AnalUnited States, France, Belgium
-
National Cancer Institute (NCI)NRG OncologyCompletedRectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage II Rectal Cancer AJCC v7United States, Puerto Rico
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
National Cancer Institute (NCI)TerminatedStage III Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage II Rectal Cancer AJCC v8 | Locally Advanced Rectal CarcinomaUnited States
-
City of Hope Medical CenterWithdrawnRecurrent Rectal Cancer | Stage I Rectal Cancer | Stage II Rectal Cancer | Stage III Rectal Cancer
-
Peking University Third HospitalRecruitingRectal Cancer Stage II | Rectal Cancer Stage IIIChina
-
Prof. Dr. med. Claus RödelJohann Wolfgang Goethe University Hospital; Deutsche Krebshilfe e.V., Bonn...CompletedRectal Neoplasms | Rectal Cancer Stage II | Rectal Cancer Stage IIIGermany
-
National Cancer Institute (NCI)CompletedRectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage II Rectal Cancer AJCC v7United States
Clinical Trials on injection of indigo carmine
-
Weill Medical College of Cornell UniversityCompletedBrain Tumors With Ill-defined MarginsUnited States
-
Karolinska University HospitalUnknownLymphocytic Colitis | Collagenous Colitis | Chronic DiarrhoeaSweden
-
Karolinska University HospitalUnknownUlcerative Colitis | Crohn's ColitisSweden
-
Hospital Universitario de MóstolesCompletedColonic Polyp | Colonic Neoplasms | Colonic Cancer
-
The Leeds Teaching Hospitals NHS TrustUnknown
-
King's College Hospital NHS TrustCompletedInflammatory Bowel DiseaseUnited Kingdom
-
VA Office of Research and DevelopmentCompletedColorectal NeoplasmsUnited States
-
Hillel Yaffe Medical CenterUnknownInflammatory Bowel DiseasesIsrael
-
Mayo ClinicCompletedColonic PolypsUnited States
-
Boehringer IngelheimCompletedMyocardial InfarctionChina, Korea, Republic of, Hong Kong